Background: Risk factors for psoriasis have been identified. Objective: To precisely define these associated factors. Methods: A survey was conducted using a questionnaire on a representative sample of the French population. A case-control study was conducted. Cases were persons who declared having had psoriasis during the previous 12 months. For each case, 3 matched controls were selected. Cases and controls were compared using univariate and multivariate analyses. Results: The questionnaire was filled out and returned by 6,887 (68.9%) of 10,000 subjects aged 15 years and over; 356 cases were identified. In multivariate analysis, a higher body mass index, current and former smoking habits and β-blocker intake were independently associated with a higher risk of psoriasis; intake of statins was associated with a decreased risk (p < 0.05). Conclusions: We confirmed the association of overweight, smoking habits and β-blocker intake with psoriasis and reported a decreased risk associated with statin intake.

Keywords:
Psoriasis, risk factors, Community survey, France
1.
Langley RG, Krueger GG, Griffiths CE: Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64 (suppl 2):ii18–23, discussion ii24–25.
2.
Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442–447.
3.
Krueger G, Ellis CN: Psoriasis – recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005;53:S94–S100.
4.
Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136–139.
5.
Wolkenstein P, Grob JJ, Bastuji-Garin S, Ruszczynski S, Roujeau JC, Revuz J: French people and skin diseases: results of a survey using a representative sample. Arch Dermatol 2003;139:1614–1619.
6.
Braathen LR, Botten G, Bjerkedal T: Prevalence of psoriasis in Norway. Acta Derm Venereol Suppl (Stockh) 1989;142:5–8.
7.
Falk ES, Vandbakk O: Prevalence of psoriasis in a Norwegian Lapp population. Acta Derm Venereol Suppl (Stockh) 1993;182:6–9.
8.
Nevitt GJ, Hutchinson PE: Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 1996;135:533–537.
9.
Rea JN, Newhouse ML, Halil T: Skin disease in Lambeth: a community study of prevalence and use of medical care. Br J Prev Soc Med 1976;30:107–114.
10.
Yip SY: The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 1984;10:965–968.
11.
Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ: The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005;52:23–26.
12.
Kavli G, Forde OH, Arnesen E, Stenvold SE: Psoriasis: familial predisposition and environmental factors. Br Med J (Clin Res Ed) 1985;291:999–1000.
13.
Kavli G, Stenvold SE, Vandbakk O: Low prevalence of psoriasis in Norwegian Lapps. Acta Derm Venereol 1985;65:262–263.
14.
Quirk CJ: Skin disease in the Busselton population survey. Med J Aust 1979;1:569–570.
15.
Lindegard B: Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298–304.
16.
Naldi L, Colombo P, Placchesi EB, Piccitto R, Chatenoud L, La Vecchia C: Study design and preliminary results from the pilot phase of the Praktis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology 2004;208:38–42.
17.
Lomholt G: Prevalence of skin diseases in a population: a census study from the Faroe Islands. Dan Med Bull 1964;11:1–7.
18.
Brandrup F, Green A: The prevalence of psoriasis in Denmark. Acta Derm Venereol 1981;61:344–346.
19.
Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ: Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005;141:1537–1541.
20.
Koo J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485–496.
21.
Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, Krueger GG: Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527–1534.
22.
Marino MG, Carboni I, De Felice C, Maurici M, Maccari F, Franco E: Risk factors for psoriasis: a retrospective study on 501 outpatients clinical records. Ann Ig 2004;16:753–758.
23.
Naldi L, Chatenoud L, Linder D, Belloni FA, Peserico A, Virgili AR, Bruni PL, Ingordo V, Lo SG, Solaroli C, Schena D, Barba A, Di Landro A, Pezzarossa E, Arcangeli F, Gianni C, Betti R, Carli P, Farris A, Barabino GF, La Vecchia C: Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61–67.
24.
Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L, Halevy S: Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol 2005;85:299–303.
25.
Marquart-Elbaz C, Grosshans E, Lipsker D, Lipsker D: Sartans, angiotensin II receptor antagonists, can induce psoriasis. Br J Dermatol 2002;147:617–618.
26.
Enquête Emploi 2002. Paris, Institut National de la Statistique et des Etudes Economiques, 2001.
27.
Cumming RG: Is probability sampling always better? A comparison of results from a quota and a probability sample survey. Community Health Stud 1990;14:132–137.
28.
Deville JC: A theory of quota surveys. Surv Methodol 1991;17:163–181.
29.
Walter SD: The feasibility of matching and quota sampling in epidemiologic studies. Am J Epidemiol 1989;130:379–389.
30.
Jagou M, Bastuji-Garin S, Bourdon-Lanoy E, Penso-Assathiany D, Roujeau JC: Poor agreement between self-reported and dermatologists’ diagnoses for five common dermatoses. Br J Dermatol 2006;155:1006–1012.
31.
Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401–407.
32.
Sampogna F, Tabolli S, Soderfeldt B, Axtelius B, Aparo U, Abeni D: Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006;154:844–849.
33.
Mease PJ, Menter MA: Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006;54:685–704.
34.
Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D: Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 2006;154:325–331.
35.
Fouere S, Adjadj L, Pawin H: How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005;19(suppl 3):2–6.
36.
Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G: Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005;152:289–295.
37.
Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ: Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704–708.
38.
Zachariae R, Zachariae C, Ibsen HH, Mortensen JT, Wulf HC: Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients. Acta Derm Venereol 2004;84:205–212.
39.
Sampogna F, Sera F, Abeni D: Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004;122:602–607.
40.
Richards HL, Fortune DG, Main CJ, Griffiths CE: Stigmatization and psoriasis. Br J Dermatol 2003;149:209–211.
41.
Wahl AK, Gjengedal E, Hanestad BR: The bodily suffering of living with severe psoriasis: in-depth interviews with 22 hospitalized patients with psoriasis. Qual Health Res 2002;12:250–261.
42.
Rapp SR, Cottrell CA, Leary MR: Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol 2001;145:610–616.
43.
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280–284.
44.
Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M: Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000;80:430–434.
45.
Wahl A, Loge JH, Wiklund I, Hanestad BR: The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000;43:803–808.
46.
Scharloo M, Kaptein AA, Weinman J, Bergman W, Vermeer BJ, Rooijmans HG: Patients’ illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol 2000;142:899–907.
47.
Wahl A, Hanestad BR, Wiklund I, Moum T: Coping and quality of life in patients with psoriasis. Qual Life Res 1999;8:427–433.
48.
Gupta MA, Gupta AK: Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol 1997;36:259–262.
49.
McKenna KE, Stern RS: The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997;36:388–394.
50.
Gupta MA, Gupta AK: Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 1995;34:700–703.
51.
Sampogna F, Tabolli S, Mastroeni S, Di Pietro C, Fortes C, Abeni D: Quality of life impairment and psychological distress in elderly patients with psoriasis. Dermatology 2007;215:341–347.
52.
Schmitt JM, Ford DE: Role of depression in quality of life for patients with psoriasis. Dermatology 2007;215:17–27.
53.
Finlay AY, Coles EC: The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:236–244.
54.
Katugampola RP, Hongbo Y, Finlay AY: Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol 2005;152:1256–1262.
55.
Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern RS: Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol 2006;126:1480–1489.
56.
Uttjek M, Dufaker M, Nygren L, Stenberg B: Psoriasis care consumption and expectations from a gender perspective in a psoriasis population in northern Sweden. Acta Derm Venereol 2005;85:503–508.
57.
de Korte J, Van Onselen J, Kownacki S, Sprangers MA, Bos JD: Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. J Eur Acad Dermatol Venereol 2005;19:35–41.
58.
Basarab T, Munn SE, Jones RR: Diagnostic accuracy and appropriateness of general practitioner referrals to a dermatology out-patient clinic. Br J Dermatol 1996;135:70–73.
59.
Fleischer AB Jr, Feldman SR, McConnell RC: The most common dermatologic problems identified by family physicians, 1990–1994. Fam Med 1997;29:648–652.
60.
van de Kerkhof PC, de Hoop D, de Korte J, Cobelens SA, Kuipers MV: Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000;200:292–298.
61.
Naldi L, Peli L, Parazzini F: Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch Dermatol 1999;135:1479–1484.
62.
Fortes C, Mastroeni S, Leffondre K, Sampogna F, Melchi F, Mazzotti E, Pasquini P, Abeni D: Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005;141:1580–1584.
63.
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G: Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68–73.
64.
Setty AR, Curhan G, Choi HK: Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med 2007;167:1670–1675.
65.
Endres M: Statins: potential new indications in inflammatory conditions. Atheroscler Suppl 2006;7:31–35.
66.
Menge T, Hartung HP, Stuve O: Statins – a cure-all for the brain? Nat Rev Neurosci 2005;6:325–331.
67.
Namazi MR: Statins: novel additions to the dermatologic arsenal? Exp Dermatol 2004;13:337–339.
68.
Behnam SM, Behnam SE, Koo JY: Alcohol as a risk factor for plaque-type psoriasis. Cutis 2005;76:181–185.
69.
Naldi L, Parazzini F, Brevi A, Peserico A, Veller FC, Grosso G, Rossi E, Marinaro P, Polenghi MM, Finzi A: Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 1992;127:212–217.
70.
Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004–2013.
71.
Kragballe K, Fogh K: A low-fat diet supplemented with dietary fish oil (Max-EPA) results in improvement of psoriasis and in formation of leukotriene B5. Acta Derm Venereol 1989;69:23–28.
72.
Wolters M: Diet and psoriasis: experimental data and clinical evidence. Br J Dermatol 2005;153:706–714.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.